nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.04.2011

Hormonal Manipulation Strategies in the Management of Menstrual Migraine and Other Hormonally Related Headaches

verfasst von: Lynne T. Shuster, Stephanie S. Faubion, Richa Sood, Petra M. Casey

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Menstrual migraine and other hormonally related headaches are common in women. Falling estrogen levels or estrogen withdrawal after periods of sustained higher levels can trigger migraine. It makes sense to target this trigger for management of hormonally related headaches, particularly when nonhormonal strategies have been unsuccessful. Decision making regarding the use of hormonal contraception and menopausal hormone therapy is complex and commonly driven by other factors, but hormonal manipulation can potentially improve the course of migraine. Providers caring for migraineurs are appropriately concerned about stroke risk. Estrogen-containing hormonal contraceptives are relatively contraindicated for women who have migraine with aura. Postmenopausal hormone therapy is acceptable for women with a history of migraine. For these women, transdermal estradiol is recommended. Estrogen replacement is important for women who undergo an early menopause, whether natural or induced. Practical strategies for hormonal manipulation in the management of migraine and other hormonally related headaches are presented.

• Victor TW, Hu X, Campbell JC, et al.: Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 30: 1065–1072, 2010. This paper provides important information on the prevalence of migraine in nearly 41,000 US men, women, and children. It provides new information on changes in migraine prevalence from childhood into adulthood, with interesting information on rates of change by age and sex. PubMedCrossRef

Nappi RE, Sances G, Detaddei S, et al.: Hormonal management of migraine at menopause. Menopause Int 15: 82–86, 2009PubMedCrossRef

Stewart WF, Wood C, Reed ML, et al.: Cumulative lifetime migraine incidence in women and men. Cephalalgia 28: 1170–1178, 2008PubMedCrossRef

Silberstein SD: Headache and female hormones: what you need to know. Curr Opin Neurol 14: 323–333, 2001PubMedCrossRef

MacGregor EA, Frith A, Ellis J, et al.: Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 67: 2154–2158, 2006PubMedCrossRef

Loder E, Rizzoli P, Golub J: Hormonal management of migraine associated with menses and the menopause: a clinical review. Headache 47: 329–340, 2007PubMedCrossRef

Beckham JC, Krug LM, Penzien DB, et al.: The relationship of ovarian steroids, headache activity and menstrual distress: a pilot study with female migraineurs. Headache 32: 292–297, 1992PubMedCrossRef

Martin VT, Wernke S, Mandell K, et al.: Defining the relationship between ovarian hormones and migraine headache. Headache 45: 1190–1201, 2005PubMedCrossRef

Martin VT, Behbehani M: Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis–part I. Headache 46: 3–23, 2006PubMedCrossRef

10.

Herzog AG: Neuroactive properties of reproductive steroids. Headache 47 Suppl 2: S68–78, 2007PubMedCrossRef

11.

Hart EC, Charkoudian N, Miller VM: Sex, Hormones and Neuroeffector Mechanisms. Acta Physiol (Oxf)

12.

Zacur HA: Hormonal changes throughout life in women. Headache 46 Suppl 2: S49–54, 2006PubMedCrossRef

13.

Martin VT, Lipton RB: Epidemiology and biology of menstrual migraine. Headache 48(Suppl 3): S124–130, 2008PubMedCrossRef

14.

Pinkerman B, Holroyd K: Menstrual and nonmenstrual migraines differ in women with menstrually-related migraine. Cephalalgia 30: 1187–1194, 2010.PubMedCrossRef

15.

The International Classification of Headache Disorders: 2nd edition. Cephalalgia 24 Suppl 1: 9–160, 2004

16.

Silberstein SD, Merriam GR: Estrogens, progestins, and headache. Neurology 41: 786–793, 1991PubMed

17.

Hudson JI, Goldenberg DL, Pope HG, Jr., et al.: Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 92: 363–367, 1992PubMedCrossRef

18.

Calhoun AH, Hutchinson S: Hormonal therapies for menstrual migraine. Curr Pain Headache Rep 13: 381–385, 2009PubMedCrossRef

19.

Somerville BW: The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 22: 355–365, 1972PubMed

20.

• ACOG Practice Bulletin No. 110: Noncontraceptive Uses of Hormonal Contraceptives. Obstet Gynecol 2010, 115: 206–218. This is a clinically focused summary from the American College of Obstetricians and Gynecologists regarding the use of hormonal contraceptives for menstrual cycle regulation, premenstrual syndrome, migraine, and other conditions.

21.

Menopause Practice: A Clinician’s Guide. The North American Menopause Society, 2007

22.

• MacGregor EA: Estrogen replacement and migraine. Maturitas 63: 51–55, 2009. This is a very useful, clinically focused summary of the literature on estrogen therapy and migraine. PubMedCrossRef

23.

Loder EW, Buse DC, Golub JR: Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review. Am J Obstet Gynecol 193: 636–649, 2005PubMedCrossRef

24.

Aegidius K, Zwart JA, Hagen K, et al.: Oral contraceptives and increased headache prevalence: the Head-HUNT Study. Neurology 66: 349–353, 2006PubMedCrossRef

25.

Tozer BS, Boatwright EA, David PS, et al.: Prevention of migraine in women throughout the life span. Mayo Clin Proc 81: 1086–1091; quiz 1092, 2006PubMedCrossRef

26.

Sulak P, Willis S, Kuehl T, et al.: Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache 47: 27–37, 2007PubMed

27.

Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ: Greater inhibition of the pituitary–ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 74: 100–103, 2006PubMedCrossRef

28.

Neri I, Granella F, Nappi R, et al.: Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas 17: 31–37, 1993PubMedCrossRef

29.

Shuster LT, Rhodes DJ, Gostout BS, et al.: Premature menopause or early menopause: long-term health consequences. Maturitas 65: 161–166

30.

•• Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17: 242–255, 2010. This is a pivotal summary of current findings regarding the benefits and risks of HT started around the time of menopause.

31.

•• Santen RJ, Allred DC, Ardoin SP, et al.: Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 95: s1–s66, 2010. This is a comprehensive scientific summary of postmenopausal HT indications, uses, risks, and benefits, with meticulous grading of evidence. It is an integrated reference source providing an extensive amount of well-summarized cumulative data on the pros and cons of postmenopausal HT. PubMedCrossRef

32.

Kaunitz AM: Hormonal Contraception in Women of Older Reproductive Age. The New England Journal of Medicine: 1262–1270, 2008

33.

Curtis KM, Mohllajee AP, Peterson HB: Use of combined oral contraceptives among women with migraine and nonmigrainous headaches: a systematic review. Contraception 73: 189–194, 2006PubMedCrossRef

34.

Bousser MG, Conard J, Kittner S, et al.: Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society Task Force on Combined Oral Contraceptives & Hormone Replacement Therapy. Cephalalgia 20: 155–156, 2000PubMedCrossRef

35.

Spector JT, Kahn SR, Jones MR, et al.: Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med 123: 612–624

36.

Kurth T, Schurks M, Logroscino G, et al.: Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ 337: a636, 2008PubMedCrossRef

37.

Loder EW, Buse DC, Golub JR: Headache and combination estrogen-progestin oral contraceptives: integrating evidence, guidelines, and clinical practice. Headache 45: 224–231, 2005PubMedCrossRef

38.

Davis PH: Use of oral contraceptives and postmenopausal hormone replacement: evidence on risk of stroke. Curr Treat Options Neurol 10: 468–474, 2008PubMedCrossRef

39.

ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 107: 1453–1472, 2006

40.

World Health Organization. Medical eligibility criteria for contraceptive use–4th ed. world Health Organization 2010, 2010

41.

Massiou H, MacGregor EA: Evolution and treatment of migraine with oral contraceptives. Cephalalgia 20: 170–174, 2000PubMedCrossRef

42.

Parker WH, Broder MS, Chang E, et al.: Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstet Gynecol 113: 1027–1037, 2009PubMed

43.

Lisabeth LD, Beiser AS, Brown DL, et al.: Age at natural menopause and risk of ischemic stroke: the Framingham heart study. Stroke 40: 1044–1049, 2009PubMedCrossRef

44.

Baba Y, Ishikawa S, Amagi Y, et al.: Premature menopause is associated with increased risk of cerebral infarction in Japanese women. Menopause 17: 506–510

45.

Rivera CM, Grossardt BR, Rhodes DJ, et al.: Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 16: 15–23, 2009PubMedCrossRef

46.

Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM: Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG 113: 5–14, 2006PubMedCrossRef

47.

Sare GM, Gray LJ, Bath PM: Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 29: 2031–2041, 2008PubMedCrossRef

48.

Renoux C, Dell’aniello S, Garbe E, Suissa S: Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 340: c2519

49.

Shufelt C, Bairey-Merz C, Prentice R, Pettinger M, Manson J, Investigators ftWsHI: Low-dose estrogen and risk of cardiovascular events: findings from the WHI observational study. The North American Menopause Society 21st Annual Meeting, Chicago, IL.

Titel: Hormonal Manipulation Strategies in the Management of Menstrual Migraine and Other Hormonally Related Headaches
verfasst von: Lynne T. Shuster
Stephanie S. Faubion
Richa Sood
Petra M. Casey
Publikationsdatum: 01.04.2011
Verlag: Current Science Inc.
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 2/2011
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-010-0174-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Risk Stratification of Medulloblastoma: A Paradigm for Future Childhood Brain Tumor Management Strategies

Migraine Chronification

The Sleep Manifestations of Frontal Lobe Epilepsy

Paraneoplastic Neurologic Disorders in Children

Treatment of Refractory Status Epilepticus in Childhood

Newly Postulated Neurodevelopmental Risks of Pediatric Anesthesia